Wuqiang Zhu1, Wenjun Zhang1, Weinian Shou1, Loren J Field2. 1. The Riley Heart Research Center, Wells Center for Pediatric Research, 1044 West Walnut Street; R4 Building Room W376, Indianapolis, IN 46202-5225, USA. 2. The Riley Heart Research Center, Wells Center for Pediatric Research, 1044 West Walnut Street; R4 Building Room W376, Indianapolis, IN 46202-5225, USA The Krannert Institute of Cardiology, Indiana University School of Medicine, 1044 West Walnut Street, Indianapolis, IN 46202, USA ljfield@iupui.edu.
Abstract
AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity. Children are particularly sensitive to DOX-induced heart failure. Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile model. METHODS AND RESULTS: Two-week-old MHC-CB7 mice (which express dominant-interfering p53 in cardiomyocytes) and their non-transgenic (NON-TXG) littermates received weekly DOX injections for 5 weeks (25 mg/kg cumulative dose). One week after the last DOX treatment (acute stage), MHC-CB7 mice exhibited improved cardiac function and lower levels of cardiomyocyte apoptosis when compared with the NON-TXG mice. Surprisingly, by 13 weeks following the last DOX treatment (late stage), MHC-CB7 exhibited a progressive decrease in cardiac function and higher rates of cardiomyocyte apoptosis when compared with NON-TXG mice. p53 inhibition blocked transient DOX-induced STAT3 activation in MHC-CB7 mice, which was associated with enhanced induction of the DNA repair proteins Ku70 and Ku80. Mice with cardiomyocyte-restricted deletion of STAT3 exhibited worse cardiac function, higher levels of cardiomyocyte apoptosis, and a greater induction of Ku70 and Ku80 in response to DOX treatment during the acute stage when compared with control animals. CONCLUSION: These data support a model wherein a p53-dependent cardioprotective pathway, mediated via STAT3 activation, mitigates DOX-induced myocardial stress during drug delivery. Furthermore, these data suggest an explanation as to how p53 inhibition can result in cardioprotection during drug treatment and, paradoxically, enhanced cardiotoxicity long after the cessation of drug treatment. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity. Children are particularly sensitive to DOX-induced heart failure. Here, the impact of p53 inhibition on acute vs. late-stage DOXcardiotoxicity was examined in a juvenile model. METHODS AND RESULTS: Two-week-old MHC-CB7 mice (which express dominant-interfering p53 in cardiomyocytes) and their non-transgenic (NON-TXG) littermates received weekly DOX injections for 5 weeks (25 mg/kg cumulative dose). One week after the last DOX treatment (acute stage), MHC-CB7 mice exhibited improved cardiac function and lower levels of cardiomyocyte apoptosis when compared with the NON-TXG mice. Surprisingly, by 13 weeks following the last DOX treatment (late stage), MHC-CB7 exhibited a progressive decrease in cardiac function and higher rates of cardiomyocyte apoptosis when compared with NON-TXG mice. p53 inhibition blocked transient DOX-induced STAT3 activation in MHC-CB7 mice, which was associated with enhanced induction of the DNA repair proteins Ku70 and Ku80. Mice with cardiomyocyte-restricted deletion of STAT3 exhibited worse cardiac function, higher levels of cardiomyocyte apoptosis, and a greater induction of Ku70 and Ku80 in response to DOX treatment during the acute stage when compared with control animals. CONCLUSION: These data support a model wherein a p53-dependent cardioprotective pathway, mediated via STAT3 activation, mitigates DOX-induced myocardial stress during drug delivery. Furthermore, these data suggest an explanation as to how p53 inhibition can result in cardioprotection during drug treatment and, paradoxically, enhanced cardiotoxicity long after the cessation of drug treatment. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Arjan B Brenkman; Niels J F van den Broek; Peter L J de Keizer; Dik C van Gent; Boudewijn M T Burgering Journal: FASEB J Date: 2010-06-22 Impact factor: 5.191
Authors: Yanti Octavia; Carlo G Tocchetti; Kathleen L Gabrielson; Stefan Janssens; Harry J Crijns; An L Moens Journal: J Mol Cell Cardiol Date: 2012-03-21 Impact factor: 5.000
Authors: Wuqiang Zhu; Mark H Soonpaa; Hanying Chen; Weihua Shen; R Mark Payne; Edward A Liechty; Randall L Caldwell; Weinian Shou; Loren J Field Journal: Circulation Date: 2008-12-22 Impact factor: 29.690
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: Jie Li; Ping-Yuan Wang; Nathaniel A Long; Jie Zhuang; Danielle A Springer; Jizhong Zou; Yongshun Lin; Christopher K E Bleck; Ji-Hoon Park; Ju-Gyeong Kang; Paul M Hwang Journal: Proc Natl Acad Sci U S A Date: 2019-09-05 Impact factor: 11.205
Authors: Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu Journal: Nat Med Date: 2016-04-18 Impact factor: 53.440
Authors: Rimpy Dhingra; Victoria Margulets; Subir Roy Chowdhury; James Thliveris; Davinder Jassal; Paul Fernyhough; Gerald W Dorn; Lorrie A Kirshenbaum Journal: Proc Natl Acad Sci U S A Date: 2014-12-08 Impact factor: 11.205